HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McCarville, M. B. Articles by Davidoff, A. M. Search for Related Content PubMed PubMed Citation Articles by McCarville, M. B. Articles by Davidoff, A. M. Related Collections Related Article

Angiogenesis Inhibitors in a Murine Neuroblastoma Model: Quantitative Assessment of Intratumoral Blood Flow with Contrast-enhanced Gray-Scale US¹

¹ From the Departments of Radiological Sciences (M.B.M.), Surgery (C.J.S., P.V.D., A.M.D.), and Biostatistics (C.S.L.), St Jude Children's Research Hospital, 332 N Lauderdale St, Memphis, TN 38105-2794; Departments of Radiology (M.B.M.) and Surgery (C.J.S., P.V.D., A.M.D.), University of Tennessee–Memphis Health Science Center, Memphis, Tenn; and Department of Haematology, University College London, London, England (A.C.N.). Received April 27, 2005; revision requested June 22; revision received August 22; final version accepted September 22. Supported by grants from the Assisi Foundation of Memphis 94-000, American Cancer Society grant IRG-87-008-09, Cancer Center Support CORE grant P30 CA 21765, and American Lebanese Syrian Associated Charities. A.M.D. supported by a Young Investigator Research Award from the Alliance for Cancer Gene Therapy. Address correspondence to M.B.M. (e-mail: beth.mccarville{at}stjude.org).

Purpose: To quantify intratumoral ultrasonographic (US) contrast agent flow at gray-scale imaging as a measure of functional tumor vascularity in an orthotopic murine neuroblastoma model treated with angiogenesis inhibitors.

Materials and Methods: After Institutional Animal Care and Use Committee approval, retroperitoneal neuroblastomas were established in mice with unmodified NXS2 cells (n = 13) or with cells engineered to overexpress an angiogenesis inhibitor—either tissue inhibitor of matrix metalloproteinase-3 (n = 22) or a truncated soluble form of the vascular endothelial growth factor receptor-2 (truncated soluble fetal liver kinase-1; n = 13). When tumors were approximately 600 mm³, contrast material–enhanced gray-scale US was performed, and the imaging was recorded on cine clips. Regions of interest within tumors were analyzed off-line to determine postcontrast change in signal intensity (SI) from baseline to initial peak (SI), rate of SI increase from baseline to initial peak (RSI), and contrast material washout. The Mann-Whitney test was used to evaluate potential differences in these US parameters between treatment groups. The mean intratumoral endothelial cell (CD34) and pericyte (smooth muscle actin [SMA]) counts at immunohistochemical analysis were also evaluated. Spearman correlation test was used to investigate the relation between US parameters and these histologic markers.

Results: The SI and RSI were lower in tumors overexpressing an angiogenesis inhibitor than in control tumors (all P < .03). Contrast material washout did not differ between groups. For the entire cohort, the RSI correlated with the immunohistochemical assessment of tumor vascularity (SMA and CD34 counts) (P < .003).

Conclusion: Quantification of intratumoral flow of a US contrast agent at gray-scale imaging shows promise for monitoring tumor vascular response to antiangiogenic therapy.

© RSNA, 2006

Related Article

Will Improved Assessment of Response to Antiangiogenic Therapies Be Achieved with Contrast-enhanced Gray-Scale US?

Jonathan B. Kruskal
Radiology 2006 240: 1-2. [Full Text] [PDF]

This article has been cited by other articles:

				T. L. Sims Jr., J. B. Hamner, R. A. Bush, R. F. Williams, J. Zhou, S. U. Kim, K. S. Aboody, M. K. Danks, and A. M. Davidoff Neural Progenitor Cell-mediated Delivery of Interferon Beta Improves Neuroblastoma Response to Cyclophosphamide Ann. Surg. Oncol., November 1, 2008; 15(11): 3259 - 3267. [Abstract] [Full Text] [PDF]

				P. V. Dickson, J. B. Hamner, T. L. Sims, C. H. Fraga, C. Y.C. Ng, S. Rajasekeran, N. L. Hagedorn, M. B. McCarville, C. F. Stewart, and A. M. Davidoff Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy Clin. Cancer Res., July 1, 2007; 13(13): 3942 - 3950. [Abstract] [Full Text] [PDF]

				P. V. Dickson, J. B. Hamner, C. J. Streck, C. Y.C. Ng, M. B. McCarville, C. Calabrese, R. J. Gilbertson, C. F. Stewart, C. M. Wilson, M. W. Gaber, et al. Continuous Delivery of IFN-{beta} Promotes Sustained Maturation of Intratumoral Vasculature Mol. Cancer Res., June 1, 2007; 5(6): 531 - 542. [Abstract] [Full Text] [PDF]

				J. B. Kruskal Will Improved Assessment of Response to Antiangiogenic Therapies Be Achieved with Contrast-enhanced Gray-Scale US? Radiology, July 1, 2006; 240(1): 1 - 2. [Full Text] [PDF]